Axithra

Axithra, a spin-off from imec and Ghent University, has secured 10 million euros in a seed round to advance its therapeutic drug monitoring (TDM) technology. The platform that Axithra is developing aims to rapidly and accurately measure drug concentrations in a patient’s blood, enabling personalized and timely adjustments to drug dosages. This is particularly critical for patients in intensive care or oncology units, as incorrect dosages can lead to reduced effectiveness or harmful side effects. The seed round was led by imec.xpand and co-led by Kurma Partners, with support from investors like Qbic, Noshaq, White Fund, and Wallonie Entreprendre, as well as corporate backers Hamamatsu Photonics and Werfen. The first application of Axithra’s technology will focus on optimizing beta-lactam antibiotics treatments in intensive care units. This breakthrough promises to improve patient outcomes, reduce hospital stays, and lower healthcare costs. Axithra leverages imec’s semiconductor expertise and the photonics technology from Ghent University, exemplifying the cross-pollination of industries for innovative solutions.